Paul Tudor Jones's XBI Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 502,000 shares of State Street SPDR S&P Biotech ETF (XBI) worth $79.44 M, representing 0.11% of the portfolio. First purchased in 2016-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in XBI, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 502,000 shares. Largest reduction occurred in Q1 2017, reducing 325,000 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's State Street SPDR S&P Biotech ETF (XBI) Holding Value Over Time
Track share changes against reported price movement
Quarterly State Street SPDR S&P Biotech ETF (XBI) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +502,000 | New Buy | 502,000 | $158.25 |
| Q3 2025 | -72,687 | Sold Out | 0 | $0.00 |
| Q2 2025 | -74,404 | Reduce 50.58% | 72,687 | $82.93 |
| Q1 2025 | +72,307 | Add 96.69% | 147,091 | $81.10 |
| Q4 2024 | +19,307 | Add 34.80% | 74,784 | $90.06 |
| Q3 2024 | +38,122 | Add 219.66% | 55,477 | $98.80 |
| Q2 2024 | -94,527 | Reduce 84.49% | 17,355 | $92.71 |
| Q1 2024 | +98,054 | Add 709.10% | 111,882 | $94.89 |
| Q4 2023 | -7,028 | Reduce 33.70% | 13,828 | $89.29 |
| Q3 2023 | +3,427 | Add 19.66% | 20,856 | $73.02 |
| Q2 2023 | +17,429 | New Buy | 17,429 | $83.20 |
| Q1 2017 | -325,000 | Sold Out | 0 | $0.00 |
| Q4 2016 | +325,000 | New Buy | 325,000 | $59.19 |
Paul Tudor Jones's State Street SPDR S&P Biotech ETF Investment FAQs
Paul Tudor Jones first purchased State Street SPDR S&P Biotech ETF (XBI) in Q4 2016, acquiring 325,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held State Street SPDR S&P Biotech ETF (XBI) for 13 quarters since Q4 2016.
Paul Tudor Jones's largest addition to State Street SPDR S&P Biotech ETF (XBI) was in Q2 2026, adding 502,000 shares worth $79.44 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 502,000 shares of State Street SPDR S&P Biotech ETF (XBI), valued at approximately $79.44 M.
As of the Q2 2026 filing, State Street SPDR S&P Biotech ETF (XBI) represents approximately 0.11% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in State Street SPDR S&P Biotech ETF (XBI) was 502,000 shares, as reported at the end of Q2 2026.